Your browser doesn't support javascript.
loading
The effect of digoxin on the quality of life in patients with heart failure.
Lader, Ellis; Egan, Debra; Hunsberger, Sally; Garg, Rekha; Czajkowski, Susan; McSherry, Frances.
Afiliação
  • Lader E; New York University School of Medicine, New York, New York, USA.
J Card Fail ; 9(1): 4-12, 2003 Feb.
Article em En | MEDLINE | ID: mdl-12612867
ABSTRACT

BACKGROUND:

The Digitalis Investigation Group (DIG) trial was a randomized double-blind placebo-controlled study that examined the effect of digoxin on mortality in 7,788 patients with heart failure and sinus rhythm. A prespecified substudy evaluated the effect of digoxin therapy on health-related quality of life (HQOL) in a subset of these patients.

METHODS:

Patients in the DIG trial had clinical heart failure and were randomized to either digoxin or placebo in addition to their baseline diuretic and angiotensin-converting enzyme therapy (n = 7,788). The patients in this substudy had HQOL measured using a self-administered questionnaire employing scales that measured general health, physical functioning, depression, anger, anxiety, life satisfaction, and disease specific measures. A subjective assessment by the investigator and a 6-minute walk test evaluated functional status. HQOL was measured at baseline and at the 4- and 12-month follow-up visits.

RESULTS:

The baseline characteristics of the patients in the quality of life substudy (n = 589) were comparable to the remaining patients in the study (n = 7,199) by age and other clinical measures, including history of prior myocardial infarction or etiology of heart failure; heart failure was of shorter duration and the ejection fraction was slightly better than in the main trial. Within the substudy, patients receiving digoxin (n = 298) or placebo (n = 291) were also similar in baseline characteristics. There was no statistically significant difference in any HQOL measure between the digoxin and the placebo groups at baseline. At the 4-month visit, only perceived health was improved in the digoxin group. At 12 months, there was no statistically significant difference in perceived health, physical functioning, Minnesota Living with Heart Failure, depression, anxiety, anger, Ladder of Life, or the 6-minute walk between the digoxin and placebo groups.

CONCLUSION:

In this subset of the DIG population, digoxin therapy had no effect on the HQOL in patients with heart failure in sinus rhythm.
Assuntos
Buscar no Google
Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Digoxina / Insuficiência Cardíaca / Antiarrítmicos Tipo de estudo: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies Aspecto: Patient_preference Limite: Aged / Female / Humans / Male / Middle aged País/Região como assunto: America do norte Idioma: En Revista: J Card Fail Ano de publicação: 2003 Tipo de documento: Article
Buscar no Google
Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Digoxina / Insuficiência Cardíaca / Antiarrítmicos Tipo de estudo: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies Aspecto: Patient_preference Limite: Aged / Female / Humans / Male / Middle aged País/Região como assunto: America do norte Idioma: En Revista: J Card Fail Ano de publicação: 2003 Tipo de documento: Article